Apollo endosurgery, inc. reports record endoscopy revenue in second quarter, raises full-year outlook conference call to discuss results today at 3:30 p.m. ct / 4:30 p.m.

Austin, tx / accesswire / august 3, 2021 / apollo endosurgery, inc. ("apollo") (nasdaq:apen), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the second quarter ended june 30, 2021. highlights achieved total revenue of $16.6 million, an increase of 194% compared to the second quarter of 2020, and a new revenue record for the company* increased endoscopic suturing system (ess) revenue 23% and intragastric balloon (igb) revenue 16% on a sequential basis compared to the first quarter of 2021 realized gross margin of 55% on favorable product mix continued rollout of x-tack™ with now more than 120 active sites, demonstrating excellent product performance, a short learning curve, and utility in a diverse range of upper and lower gi applications reported that the multi-center esg randomized interventional trial (merit) study investigators announced successful achievement of the study's primary efficacy and safety endpoints strengthened the apollo leadership team with the additions of kirk ellis as vice president of sales, steve bosrock as vice president of marketing & medical education, and jeffrey black as chief financial officer 2021 outlook based on results in the first half of 2021, the company is increasing its guidance for the full year 2021 and now expects revenue between $61-$63 million, compared to its prior guidance of $55-$57 million.
APEN Ratings Summary
APEN Quant Ranking